BMGL Fundamental Analysis - BASEL MEDICAL GROUP LTD

Name: BASEL MEDICAL GROUP LTD (BMGL) Stock
Brand: BASEL MEDICAL GROUP LTD
Rating: 1.5 (3 reviews)

Fundamental Rating

Overall BMGL gets a fundamental rating of 3 out of 10. We evaluated BMGL against 100 industry peers in the Health Care Providers & Services industry. BMGL has only an average score on both its financial health and profitability. BMGL has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

BMGL had positive earnings in the past year.

BMGL had a negative operating cash flow in the past year.

1.2 Ratios

BMGL's Return On Assets of 11.76% is amongst the best of the industry. BMGL outperforms 97.00% of its industry peers.

BMGL has a Return On Equity of 24.18%. This is amongst the best in the industry. BMGL outperforms 92.00% of its industry peers.

Looking at the Return On Invested Capital, with a value of 36.92%, BMGL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

BMGL had an Average Return On Invested Capital over the past 3 years of 29.84%. This is significantly above the industry average of 9.45%.

The last Return On Invested Capital (36.92%) for BMGL is above the 3 year average (29.84%), which is a sign of increasing profitability.

		Industry Rank	Sector Rank
ROA	11.76%
ROE	24.18%
ROIC	36.92%

ROA(3y)12.01%

ROA(5y)N/A

ROE(3y)37.76%

ROE(5y)N/A

ROIC(3y)29.84%

ROIC(5y)N/A

1.3 Margins

The Profit Margin of BMGL (11.64%) is better than 98.00% of its industry peers.

The Operating Margin of BMGL (32.46%) is better than 98.00% of its industry peers.

		Industry Rank	Sector Rank
OM	32.46%
PM (TTM)	11.64%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BMGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.

BMGL has about the same amout of shares outstanding than it did 1 year ago.

Compared to 1 year ago, BMGL has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 3.82 indicates that BMGL is not in any danger for bankruptcy at the moment.

BMGL has a better Altman-Z score (3.82) than 74.00% of its industry peers.

BMGL has a Debt/Equity ratio of 0.55. This is a neutral value indicating BMGL is somewhat dependend on debt financing.

With a decent Debt to Equity ratio value of 0.55, BMGL is doing good in the industry, outperforming 61.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.55
Debt/FCF	N/A
Altman-Z	3.82

ROIC/WACC4.23

WACC8.72%

2.3 Liquidity

BMGL has a Current Ratio of 1.88. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.

BMGL has a better Current ratio (1.88) than 72.00% of its industry peers.

A Quick Ratio of 1.87 indicates that BMGL should not have too much problems paying its short term obligations.

Looking at the Quick ratio, with a value of 1.87, BMGL is in the better half of the industry, outperforming 75.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.88
Quick Ratio	1.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BMGL have decreased strongly by -43.56% in the last year.

BMGL shows a small growth in Revenue. In the last year, the Revenue has grown by 1.99%.

EPS 1Y (TTM)-43.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-123.92%

Revenue 1Y (TTM)1.99%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-1.07%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BMGL is valuated rather expensively with a Price/Earnings ratio of 20.86.

Compared to the rest of the industry, the Price/Earnings ratio of BMGL indicates a somewhat cheap valuation: BMGL is cheaper than 64.00% of the companies listed in the same industry.

BMGL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.28.

		Industry Rank	Sector Rank
PE	20.86
Fwd PE	N/A

4.2 Price Multiples

BMGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMGL is cheaper than 96.00% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	3.95

4.3 Compensation for Growth

BMGL has a very decent profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BMGL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (11/11/2025, 4:03:36 PM)

1.46

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners0.7%

Inst Owner ChangeN/A

Ins Owners13.65%

Ins Owner ChangeN/A

Market Cap27.43M

Revenue(TTM)15.09M

Net Income(TTM)1.76M

AnalystsN/A

Price TargetN/A

Short Float %4.17%

Short Ratio2.05

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	20.86
Fwd PE	N/A
P/S	2.37
P/FCF	N/A
P/OCF	N/A
P/B	4.92
P/tB	4.92
EV/EBITDA	3.95

EPS(TTM)0.07

EY4.79%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.06

FCFYN/A

OCF(TTM)-0.06

OCFYN/A

SpS0.62

BVpS0.3

TBVpS0.3

PEG (NY)N/A

PEG (5Y)N/A

Graham Number0.68

Profitability

		Industry Rank	Sector Rank
ROA	11.76%
ROE	24.18%
ROCE	67.42%
ROIC	36.92%
ROICexc	1026.25%
ROICexgc	1026.25%
OM	32.46%
PM (TTM)	11.64%
GM	N/A
FCFM	N/A

ROA(3y)12.01%

ROA(5y)N/A

ROE(3y)37.76%

ROE(5y)N/A

ROIC(3y)29.84%

ROIC(5y)N/A

ROICexc(3y)34.59%

ROICexc(5y)N/A

ROICexgc(3y)34.59%

ROICexgc(5y)N/A

ROCE(3y)47.14%

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover1.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0.55
Debt/FCF	N/A
Debt/EBITDA	0.73
Cap/Depr	2.99%
Cap/Sales	0.12%
Interest Coverage	27.55
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.88
Quick Ratio	1.87
Altman-Z	3.82

F-Score3

WACC8.72%

ROIC/WACC4.23

Cap/Depr(3y)5.99%

Cap/Depr(5y)N/A

Cap/Sales(3y)0.32%

Cap/Sales(5y)N/A

Profit Quality(3y)134.28%

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-43.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-123.92%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)1.99%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-1.07%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-34.23%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-3.56%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-3.49%

OCF growth 3YN/A

OCF growth 5YN/A

BASEL MEDICAL GROUP LTD / BMGL FAQ

What is the fundamental rating for BMGL stock?

ChartMill assigns a fundamental rating of 3 / 10 to BMGL.

What is the valuation status of BASEL MEDICAL GROUP LTD (BMGL) stock?

ChartMill assigns a valuation rating of 2 / 10 to BASEL MEDICAL GROUP LTD (BMGL). This can be considered as Overvalued.

How profitable is BASEL MEDICAL GROUP LTD (BMGL) stock?

BASEL MEDICAL GROUP LTD (BMGL) has a profitability rating of 6 / 10.

What are the PE and PB ratios of BASEL MEDICAL GROUP LTD (BMGL) stock?

The Price/Earnings (PE) ratio for BASEL MEDICAL GROUP LTD (BMGL) is 20.86 and the Price/Book (PB) ratio is 4.92.

BASEL MEDICAL GROUP LTD (BMGL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BASEL MEDICAL GROUP LTD / BMGL FAQ

What is the fundamental rating for BMGL stock?

What is the valuation status of BASEL MEDICAL GROUP LTD (BMGL) stock?

How profitable is BASEL MEDICAL GROUP LTD (BMGL) stock?

What are the PE and PB ratios of BASEL MEDICAL GROUP LTD (BMGL) stock?